Document:

Exhibit 10.5

 

CONFIDENTIAL TREATMENT REQUESTED UNDER

C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406.

[****] INDICATES OMITTED MATERIAL THAT IS THE

SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST

FILED SEPARATELY WITH THE COMMISSION.

THE OMITTED MATERIAL HAS BEEN FILED

SEPARATELY WITH THE COMMISSION.

 

AMENDMENT #3 to the LICENSE AGREEMENT

 

This
Amendment No. 3 (“Amendment No. 3”) is made by and between the
Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences, a
public institution of higher education having principal offices at 2404 North University Avenue, Little Rock, Arkansas 72207 (hereinafter
“University”), and Myeloma Health LLC, a Delaware limited liability company having a principal office at 667 Madison
Avenue, 14th Floor, New York, New York 10065 (hereinafter “Licensee”).

 

WITTNESSETH

 

WHEREAS, on April 1, 2010, the University
and Licensee entered into a License Agreement (“AGREEMENT”).

 

WHEREAS, the University and Licensee wish
to amend the Agreement to add to the scope of the PATENT RIGHTS (as such term is defined in the AGREEMENT) any patent applications
filed by or on behalf of UNIVERSITY which disclose the inventions or discoveries of UNIVERSITY disclosure number 2011-30.

 

Amendments

 

NOW, THEREFORE, the University and Licensee,
in consideration of the premises and the mutual covenants contained herein, hereby agree as follows:

 

		1.	This Amendment is made effective as of October _____, 2011 (“Third Amendment Date”).

 

		2.	UNIVERSITY and LICENSEE acknowledge and agree that any patent applications filed by or on behalf
of UNIVERSITY which disclose the inventions or discoveries of UAMS Disclosure Number 2011-30 shall be added to the scope of the
PATENT RIGHTS under Section 2.12(a). As a consequence, Appendix A shall be revised to include the following new table entries:

 

	“[****]”
	UAMS Disclosure #	Applications	Publications	U.S. Patents	Overseas Publications	Overseas Patents
	[****]	[****]	 	[****]	 	 

 

		3.	Within ninety (90) days of the Third Amendment Date, LICENSEE shall pay to UNIVERSITY a one-time payment of [****] dollars
($[****]), which payment shall be in addition to any payments due under the AGREEMENT.

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED UNDER

C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406.

[****] INDICATES OMITTED MATERIAL THAT IS THE

SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST

FILED SEPARATELY WITH THE COMMISSION.

THE OMITTED MATERIAL HAS BEEN FILED

SEPARATELY WITH THE COMMISSION.

 

		4.	All other terms and conditions of the Agreement that have not been amended herein shall remain in full force and effect.

 

		5.	The recitals and preamble set forth prior to the enumerated sections of this Amendment are hereby incorporated by reference
in their entirety and made a part of this Amendment as if fully set forth herein.

 

IN WITNESS WHEREOF, the parties have caused this Amendment to
be executed by their duly authorized representatives.

 

	BOARD OF TRUSTEES OF THE 

UNIVERSITY OF ARKANSAS	 	MYELOMA HEALTH LLC
	 	 	 	 	 
	By:	/s/ Ann Kemp	 	By:	/s/ Joe Hernandez
	Name: 	Ann Kemp	 	Name: 	Joe Hernandez
	 	 	 	 	 
	Title:	Vice President for Administration	 	Title:	President and CEOExhibit 10.6

 

AMENDMENT #4 to the LICENSE AGREEMENT

 

This
Amendment (“Amendment”) is made by and between the Board of Trustees of the University of Arkansas acting
for and on behalf of the University of Arkansas for Medical Sciences, a public institution of higher education having principal
offices at 2404 North University Avenue, Little Rock, Arkansas 72207 (hereinafter “University”), and Myeloma
Health LLC, a Delaware limited liability company having a principal office at 667 Madison Avenue, 14th Floor, New York,
New York 10065 (hereinafter “Licensee”).

 

WITTNESSETH

 

WHEREAS, on April 1, 2010, the University
and Licensee entered into a license agreement (“Agreement”),

 

WHEREAS, the University and Licensee wish
to amend the Agreement.

 

Amendments

 

NOW, THEREFORE, the University and Licensee,
in consideration of the premises and the mutual covenants contained herein, hereby agree as follows:

 

		1.	This Amendment is made effective as of ___12/1/11_______.

 

		2.	Article 7.1 of the Agreement shall be replaced as follows:

 

(a)          LICENSEE shall have the
obligation, exclusive right and license, in the name of and on behalf of UNIVERSITY, to apply for, prosecute, seek prompt issuance
of, maintain, and pay all costs associated with, during the term of this Agreement, the PATENT RIGHTS (including, without limitations,
all applications included therein) listed in Appendix A, including, without limitation, all United States and foreign patents issued
from the patent applications listed in Appendix A and from any patent application that is a divisional, continuation, continuation-in-part
(but only to the extent supported in the specification, and entitled to the priority date of, the parent application), and any
reexamination and reissue of any patent and/or patent application listed in Appendix A and any divisional, continuation, continuation-in-part
(but only to the extent supported in the specification, and entitled to the priority date of, the parent application), reexamination
and reissue issued from such an application and any foreign patent issued from any corresponding foreign patent application (“Appendix
A PATENT RIGHTS”). The prosecution, filing and maintenance of the Appendix A PATENT RIGHTS patents and applications shall
be the primary responsibility of LICENSEE, including payment of all costs associated therewith; provided, however, that UNIVERSITY
shall have reasonable opportunities to advise LICENSEE and shall cooperate with LICENSEE in such prosecution, filing and maintenance
as requested by LICENSEE. LICENSEE shall have the right to select counsel to prosecute the Appendix A PATENT RIGHTS, subject to
approval by UNIVERSITY which approval shall not be unreasonably withheld. LICENSEE shall consult with UNIVERSITY prior to taking
any action which is reasonably likely to have a material adverse effect upon the UNIVERSITY’S rights in the Appendix A PATENT
RIGHTS. Copies of all Patent Office actions shall be provided at their time of receipt and copies of responses thereto shall be
provided to UNIVERSITY and its designated patent counsel prior to their filing and with sufficient time for UNIVERSITY and its
designated patent counsel to provide comments and recommendations if deemed necessary, which comments and recommendations will
be duly considered by LICENSEE in the prosecution and maintenance of the Appendix A PATENT RIGHTS. LICENSEE shall apply for and
use its reasonable good faith efforts to prosecute and seek prompt issuance of the Appendix A PATENT RIGHTS in the United States
and in such foreign countries as shall be agreed to by UNIVERSITY and LICENSEE, in a timely and reasonably prudent business manner.
LICENSEE shall use good faith efforts to maintain the Appendix A PATENT RIGHTS during the term of this Agreement in such countries
as LICENSEE deems necessary in the exercise of its reasonably prudent business judgment; provided that UNIVERSITY shall be notified
prior to the abandonment of any patent or patent application included in the Appendix A PATENT RIGHTS. UNIVERSITY reserves the
right to prosecute and maintain, at its sole expense, any patent or patent application included in the PATENT RIGHTS that is abandoned
by LICENSEE (except for purposes of filing continuation applications) and LICENSEE shall have no license or rights to such patents
or patent applications.

 

    	 

    	 

    

 

(b)          UNIVERSITY shall apply for,
seek prompt issuance of, and maintain during the term of this Agreement the PATENT RIGHTS listed in Appendix B (“Appendix
B PATENT RIGHTS”) unless otherwise agreed by the LICENSEE and any third party that is also a licensee with respect to a patent
application or patent within such Appendix B PATENT RIGHTS, provided, however, that LICENSEE and, if applicable,
any such third party licensee shall: (i) agree upon and select patent counsel to be used by the UNIVERSITY (and shall select new
patent counsel from time to time as LICENSEE, UNIVERSITY and any such third party licensee may agree) and (ii) have the opportunity
to review and comment on decisions to be made or answers to examiner comments, which comments shall be duly considered and included
in any proposed amendments. UNIVERSITY shall keep LICENSEE regularly updated of the status of the patent application filings. UNIVERSITY
agrees to consult LICENSEE to determine in which countries the application has to be extended and to extend the patent application
in the countries selected by LICENSEE and any applicable third party licensee of the Appendix B PATENT RIGHTS. UNIVERSITY shall
diligently file, prosecute and maintain the patent applications. The prosecution, filing and maintenance of all Appendix B PATENT
RIGHTS patents shall be the primary responsibility of UNIVERSITY as set forth in this Article 7, provided that this Article 7 shall
be subject to the terms and conditions set forth in Article 5.1(e) of this Agreement.

 

		3.	All other terms and conditions of the Agreement that have not been amended herein shall remain
in full force and effect.

 

    	- 2 -

    	 

    

 

		4.	The recitals and preamble set forth prior to the enumerated sections of this Amendment are hereby
incorporated by reference in their entirety and made a part of this Amendment as if fully set forth herein.

 

IN WITNESS WHEREOF, the parties have caused
this Amendment to be executed by their duly authorized representatives.

 

	BOARD OF TRUSTEES OF THE 

UNIVERSITY OF ARKANSAS	 	MYELOMA HEALTH LLC
	 	 	 	 	 
	By:	/s/ Ann Kemp	 	By:	/s/ Joe Hernandez
	 	 	 	 	 
	Name: 	Ann Kemp	 	Name: 	Joe Hernandez
	 	 	 	 	 
	Title:	Vice President for Administration	 	Title:	President and CEO

 

    	- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]